These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38768766)

  • 21. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
    Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
    Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving physicochemical properties and pharmacological activities of ternary co-amorphous systems.
    Fang X; Hu Y; Yang G; Shi W; Lu S; Cao Y
    Eur J Pharm Biopharm; 2022 Dec; 181():22-35. PubMed ID: 36283631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan.
    Wang Y; Grohganz H; Rades T
    Int J Pharm; 2022 Apr; 617():121625. PubMed ID: 35259442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil.
    Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L
    Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
    Sun DD; Lee PI
    J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The development of co-amorphous drug systems].
    Yao J; Shi NQ; Wang XL
    Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-amorphous palbociclib-organic acid systems with increased dissolution rate, enhanced physical stability and equivalent biosafety.
    Zhang M; Xiong X; Suo Z; Hou Q; Gan N; Tang P; Ding X; Li H
    RSC Adv; 2019 Jan; 9(7):3946-3955. PubMed ID: 35518078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability.
    Mukesh S; Joshi P; Bansal AK; Kashyap MC; Mandal SK; Sathe V; Sangamwar AT
    Mol Pharm; 2021 Jun; 18(6):2334-2348. PubMed ID: 34003656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
    Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
    AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in co-amorphous drug formulations.
    Dengale SJ; Grohganz H; Rades T; Löbmann K
    Adv Drug Deliv Rev; 2016 May; 100():116-25. PubMed ID: 26805787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of co-milling on dissolution rate of poorly soluble drugs.
    Slámová M; Prausová K; Epikaridisová J; Brokešová J; Kuentz M; Patera J; Zámostný P
    Int J Pharm; 2021 Mar; 597():120312. PubMed ID: 33540023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review.
    Kapoor DU; Singh S; Sharma P; Prajapati BG
    AAPS PharmSciTech; 2023 Dec; 24(8):253. PubMed ID: 38062314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of preparation technique on co-amorphization of carvedilol with acidic amino acids.
    Mishra J; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2018 Dec; 552(1-2):407-413. PubMed ID: 30278256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.
    Jensen KT; Löbmann K; Rades T; Grohganz H
    Pharmaceutics; 2014 Jul; 6(3):416-35. PubMed ID: 25025400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
    Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of polymer addition on the amorphization, dissolution and physical stability of co-amorphous systems.
    Liu J; Grohganz H; Rades T
    Int J Pharm; 2020 Oct; 588():119768. PubMed ID: 32798592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (Co-)amorphization of enantiomers - Investigation of the amorphization process, the physical stability and the dissolution behavior.
    Holzapfel K; Liu J; Rades T; Leopold CS
    Int J Pharm; 2022 Mar; 616():121552. PubMed ID: 35131351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.